Is Silicon Valley ready for biotech’s newest unethical prodigies?
<p>The future was looking unbelievably bright for <a href="https://www.forbes.com/30-under-30-2017/healthcare/#330636a34f78" rel="noopener ugc nofollow" target="_blank">Forbes 30-under-30</a> healthcare golden boy Gabriel Otte, CEO of liquid biopsy startup <a href="https://www.freenome.com/" rel="noopener ugc nofollow" target="_blank">Freenome</a>, the recipient of $65M in seed funding from Silicon Valley venture capital firm Andreessen Horowitz, also known as a16z. A Cornell graduate who worked at Apple at 17, Otte enrolled as a graduate student at the University of Pennsylvania in 2011, working in the lab of <a href="https://hosting.med.upenn.edu/epigenetics/berger/" rel="noopener ugc nofollow" target="_blank">Dr. Shelley Berger</a> within the Genomics and Computational Biology (GCB) program. Otte then left prematurely under somewhat murky circumstances — according to him, “[on leave because] starting a company violated my PhD contract” </p>
<p><a href="https://medium.com/@jermdemo/is-silicon-valley-ready-for-biotechs-newest-unethical-prodigies-c94e0f4f093e"><strong>Read More</strong></a></p>